Delcath Systems, Inc. reported total revenue of $19.8 million for the first quarter ended March 31, 2025, a substantial increase from $3.1 million in the same period of the prior year. U.S. sales of HEPZATO KIT contributed $18.0 million, while CHEMOSAT sales in Europe accounted for $1.8 million.
The company achieved its first quarter of net income, reporting $1.1 million, a significant improvement from a net loss of $11.1 million in Q1 2024. Non-GAAP adjusted EBITDA also turned positive, reaching $7.6 million compared to a loss of $7.3 million in the prior year.
Delcath generated $2.2 million in cash from operating activities during Q1 2025, marking its first quarter of positive operating cash flow. As of March 31, 2025, the company held $58.9 million in cash and investments and remained debt-free. The number of active treatment centers expanded to 17 by quarter-end, up from 4 in Q1 2024, with an additional two centers becoming active since the quarter ended.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.